YECO

EV Biologics, Inc. [YECO] Stock Forecast

Q: What is EV Biologics, Inc. stock symbol ?

EV Biologics, Inc. is a US stock, located in Cheyenne of Wy and trading under the symbol YECO

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

YECO Stock Summary

Earnings are expected to fall -100% next year

Does not have any significance market cap ($4.35M)

YECO has less than 1 year of cash runway

In the News

09:00 16 Apr 2024 YECO

EV Biologics Updates on NFT Minting

NASHVILLE, TN / ACCESSWIRE / September 28, 2021 / EV Biologics Corp, OTC PINK:YECO, today updated shareholders with further details about its NFT and minting progress. Our NFT team has been minting the NFT, designated rEVerie, on the Ghostmarket.io platform, with an estimated completion date this week.

09:00 16 Apr 2024 YECO

EV Biologics Updates on NFT Warrant Dividend Distribution

NASHVILLE, TN / ACCESSWIRE / August 30, 2021 / EV Biologics Corp, (OTC Pink:YECO), today updated shareholders with further details about its NFT Warrant Dividend distribution. The Company is currently finalizing its filing with FINRA, and then will have its transfer agent issue the dividend Warrant through DTC.

09:00 16 Apr 2024 YECO

EV Biologics Briefs Shareholders on Market Cap Peer Comparison

NASHVILLE, TN / ACCESSWIRE / August 12, 2021 / EV Biologics Corp, OTC Pink:YECO, today briefed shareholders on its current value compared to other public biotechnology companies in its peer group. Please view the chart at: https://www.evbiologics.com/marketcap/.

09:00 16 Apr 2024 YECO

EV Biologics NFT Dividend Information

NASHVILLE, TN / ACCESSWIRE / August 9, 2021 / EV Biologics Corp, OTC PINK:YECO, today updated shareholders with further details about its NFT Warrant Dividend. Attached is a preliminary image from the 3D animation still under development that will be issued as an NFT dividend Daniel Mckinney CEO said: "this NFT will capture the stunning visual quality inherent in many biological systems, as in this artistic rendering of a fluorescent micrograph of a group of stem cells.

09:00 16 Apr 2024 YECO

EV Biologics NFT Dividend Warrant Date

NASHVILLE, TN / ACCESSWIRE / July 30, 2021 / EV Biologics Corp., OTC PINK:YECO, today confirmed for share holders its NFT Warrant Dividend shareholders-of-record date. YECO's shareholders-of-record on July 30, 2021 will receive the Warrant.

09:00 16 Apr 2024 YECO

EV Biologics Starts Custom Cell Isolation with Lonza Cell Bio Services

NASHVILLE, TN / ACCESSWIRE / July 28, 2021 / EV Biologics Corp, OTC PINK:YECO today announced that it has signed an agreement with Lonza Cell Bio Services to implement a custom cell isolation in preparation for a novel, clonal, master cell bank. These cells will also be used in optimization of the process for production of therapeutically active, native, extracellular vesicles and particles (EVP).

09:30 16 Apr 2024 YECO

EV Biologics Unveils NFT Dividend Warrant

NASHVILLE, TN / ACCESSWIRE / July 26, 2021 / EV Biologics Corp, OTC PINK:YECO, today updated shareholders about its NFT dividend Warrant. The Company will distribute one (1) Warrant for every 100 shares of YECO common stock held.

09:30 16 Apr 2024 YECO

EV Biologics Signs LOI with Lonza Cell & Gene Therapy

NASHVILLE, TN / ACCESSWIRE / July 22, 2021 / EV Biologics Corp., (OTC PINK:YECO) today announced that it has signed a Letter of Intent (LOI) with Lonza Cell & Gene Therapy for Process Development and Gap Analysis for biomanufacturing of a novel therapeutic composition, comprising extracellular vesicles (EVs) and particles, as well as other secreted factors derived from selected stem/progenitor cells, such as mesenchymal stromal cells (MSCs). Lonza is one of the leading global manufacturers serving the biotechnology and pharmaceutical industries.

09:30 16 Apr 2024 YECO

EV Biologics Confirms Funding to Commence Cell Line Generation & Advance Exosome Research

NASHVILLE, TN / ACCESSWIRE / April 8, 2021 / EV Biologics Corp (OTC PINK:YECO) today announced that it has signed a director's loan agreement to secure funding of up to $5 million to start generation of a novel exosome-producer cell line and production of therapeutic exosomes for preclinical research. The Company has finalized its preparation and is ready to begin generation of a novel exosome-producer master cell bank to enable manufacturing of therapeutic exosomes with improved intrinsic bioactivity at a commercially relevant scale.

YECO Financial details

Company Rating

Sell

Market Cap

4.35M

Income

-1.04M

Revenue

48.9K

Book val./share

-0.16

Cash/share

0.01

Dividend

Dividend %

Employees

284

Optionable

Shortable

Yes

Earnings

31 Dec 2017

P/E

Forward P/E

PEG

P/S

0.65

P/B

P/C

60.21

P/FCF

-16.22

Quick Ratio

0.56

Current Ratio

3.11

Debt / Equity

-0.89

LT Debt / Equity

EPS (TTM)

-0.13

EPS next Y

EPS next Q

EPS this Y

-95.88%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

-55.83%

SMA20

2.86%

SMA50

SMA100

Inst Own

Inst Trans

ROA

-1%

ROE

-2%

ROC

Gross Margin

16%

Oper. Margin

Profit Margin

-6%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

0.563-1.95

52W High

52W Low

RSI

38.16

Rel Volume

2.17

Avg Volume

106

Volume

230

Perf Week

-14.35%

Perf Month

-14.23%

Perf Quarter

Perf Half Y

-45.26%

Beta

0.390943

Volatility

0.16%, 0.08%

Prev Close

Price

0.6021

Change

YECO Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0.02	0	0
Net income per share	-0.02	-0.01	-0.05	-2.91	-0.12
Operating cash flow per share	0	0.01	0.1	-2.88	-0.32
Free cash flow per share	0	0.01	-2.57	-2.88	-0.32
Cash per share	0	0.01	0.08	0.05	0.01
Book value per share	0.23	1.05	1	-1.91	-0.16
Tangible book value per share	0.23	1.05	1	-1.91	-0.16
Share holders equity per share	0.23	1.05	1	-1.91	-0.16
Interest debt per share	1.56	0	3	3.14	0.15
Market cap	322.55K	36.13M	5.85M	12.28M	10.23M
Enterprise value	10.36M	36.02M	26.93M	34.62M	11.59M
P/E ratio	-3.28	-365.06	-15.1	-0.58	-8.07
Price to sales ratio	0	0	49.22	0	209.11
POCF ratio	0	369.83	8.39	-0.59	-3.11
PFCF ratio	0	369.83	-0.32	-0.59	-3.08
P/B Ratio	0.22	4.75	0.81	-0.89	-6.07
PTB ratio	0.22	4.75	0.81	-0.89	-6.07
EV to sales	0	0	226.52	0	237.08
Enterprise value over EBITDA	-105.26	-364.03	-1.11K	-58.68	-24
EV to operating cash flow	0	368.78	38.59	-1.66	-3.53
EV to free cash flow	0	368.78	-1.45	-1.66	-3.49
Earnings yield	-0.31	0	-0.07	-1.71	-0.12
Free cash flow yield	0	0	-3.17	-1.7	-0.32
Debt to equity	6.89	0	3	-1.64	-0.89
Debt to assets	0.32	0	0.69	1.99	3.46
Net debt to EBITDA	-101.99	1.04	-868.94	-37.86	-2.83
Current ratio	0.22	0.07	0.03	0.02	0.19
Interest coverage	0	0	0	0	0
Income quality	0	-0.99	-1.8	0.99	2.59
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0.06	0	0	0	0
Capex to operating cash flow	0	0	-27.6	0	0.01
Capex to revenue	0	0	-162.03	0	-0.81
Capex to depreciation	0	0	0	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	0.28	0.57	1.1	11.2	0.68
ROIC	-0.01	-0.01	0	-0.07	2.56
Return on tangible assets	0	-0.01	-0.01	-1.84	-2.94
Graham Net	-4	-0.18	-3.24	-3.42	-0.17
Working capital	-22.99M	-1.34M	-23.41M	-24.67M	-1.72M
Tangible asset value	-550.08K	7.61M	7.22M	-13.83M	-1.68M
Net current asset value	-22.99M	-1.34M	-23.41M	-24.67M	-1.72M
Invested capital	6.89	0	3	-1.64	-0.89
Average receivables	0	2.4M	59.45K	184.45K	257.66K
Average payables	0	1.12M	0	103.41K	155.68K
Average inventory	0	200.64K	0	0	0
Days sales outstanding	0	0	365	0	1.98K
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	1	0	0.18
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.07	-0.01	-0.05	1.52	0.75
Capex per share	0	0	-2.67	0	0

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0	0
Net income per share	-1.54	-0.03	-0.03	-0.05	-0.02
Operating cash flow per share	-2.67	-0.01	-0.01	-3.21	1.97
Free cash flow per share	-2.67	-0.01	-0.02	-3.21	1.97
Cash per share	0.05	0.04	0.02	0.07	0.01
Book value per share	-1.91	-0.45	-0.47	-0.2	-0.16
Tangible book value per share	-1.91	-0.45	-0.47	-0.2	-0.16
Share holders equity per share	-1.91	-0.45	-0.47	-0.2	-0.16
Interest debt per share	3.14	0.14	0.14	0.21	0.15
Market cap	12.28M	6M	5.08M	10.84M	10.23M
Enterprise value	34.62M	6.72M	5.92M	11.83M	11.59M
P/E ratio	-0.28	-6.25	-6.95	-7.17	-10.85
Price to sales ratio	0	0	0	0	209.11
POCF ratio	-0.64	-129.81	-55.25	-0.47	0.51
PFCF ratio	-0.64	-120.75	-39.82	-0.47	0.51
P/B Ratio	-0.89	-1.86	-1.49	-7.49	-6.07
PTB ratio	-0.89	-1.86	-1.49	-7.49	-6.07
EV to sales	0	0	0	0	237.08
Enterprise value over EBITDA	-66.14	-86.53	-70.15	-54.78	-30.85
EV to operating cash flow	-1.8	-145.27	-64.43	-0.51	0.58
EV to free cash flow	-1.8	-135.13	-46.45	-0.51	0.58
Earnings yield	-0.9	-0.04	-0.04	-0.03	-0.02
Free cash flow yield	-1.57	-0.01	-0.03	-2.14	1.97
Debt to equity	-1.64	-0.31	-0.29	-1.04	-0.89
Debt to assets	1.99	3.46	5.11	2.53	3.46
Net debt to EBITDA	-42.68	-9.21	-10	-4.58	-3.64
Current ratio	0.02	0.08	0.04	0.27	0.19
Interest coverage	0	0	0	0	0
Income quality	1.74	0.19	0.5	61.46	-85.47
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0.08	0.39	0	0
Capex to revenue	0	0	0	0	-0.01
Capex to depreciation	0	0	0	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	8.13	0.58	0.52	0.49	0.29
ROIC	-0.06	0.03	0.03	-4.13	1.99
Return on tangible assets	-0.97	-0.83	-0.93	-0.64	-0.55
Graham Net	-3.42	-0.45	-0.48	-0.21	-0.17
Working capital	-24.67M	-3.24M	-3.46M	-1.49M	-1.72M
Tangible asset value	-13.83M	-3.24M	-3.42M	-1.45M	-1.68M
Net current asset value	-24.67M	-3.24M	-3.46M	-1.49M	-1.72M
Invested capital	-1.64	-0.31	-0.29	-1.04	-0.89
Average receivables	184.45K	125K	0	20.31K	152.97K
Average payables	103.41K	103.41K	0	68.47K	120.75K
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	488.31
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0.18
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	0.8	0.07	0.05	0.26	0.14
Capex per share	0	0	0	0	0

YECO Frequently Asked Questions

What is EV Biologics, Inc. stock symbol ?

EV Biologics, Inc. is a US stock , located in Cheyenne of Wy and trading under the symbol YECO

What is EV Biologics, Inc. stock quote today ?

EV Biologics, Inc. stock price is $0.6021 today.

Is EV Biologics, Inc. stock public?

Yes, EV Biologics, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Check Those

Similar Market Cap

Company Profile

Volume Average 106
Market Capitalization 4.35M
Employee 284
CEO Mr. Daniel S. McKinney
Headquarters Cheyenne,WY,US
IPO Date 2015-06-29
Website https://www.evbiologics.com

EV Biologics, Inc., a biotechnology company, engages in the commercial development of extracellular vesicles (EVs) as biological modalities for diagnostics and therapeutics. It is involved in developing vaccines, therapeutics, and cures based on its proprietary multifunctional EV platform. The company also focuses on developing human mesenchymal and other stem cell, and cell-derived products to market in the cosmetic and biopharmaceutical spaces. The company was formerly known as Yulong Eco-Materials Limited and changed its name to EV Biologics, Inc. in August 2020. EV Biologics, Inc. was incorporated in 2011 and is headquartered in Cheyenne, Wyoming.